FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376643030> ?p ?o ?g. }

• W4376643030 endingPage "264" @default.
• W4376643030 startingPage "257" @default.
• W4376643030 abstract "Immune-related adverse events (irAEs) are commonly occurred in patients treated with immune checkpoint inhibitors. However, evidence of irAEs derived from the Chinese population is relatively lacking. The aim of this study was to investigate the incidence and outcomes of irAEs in Chinese patients with lung cancer after receiving immune checkpoint inhibitors (ICIs).Clinical and follow-up data from lung cancer patients who received at least one time of ICIs from January 2018 to September 2021 at Huadong Hospital, Fudan University were included. Statistical descriptions and Kaplan-Meier method were used to analyze the overall incidence of irAEs, as well as the incidence and outcomes of each type of irAEs.135 patients were included in the study. 106 patients (78.5%) presented at least one type of irAEs, and the median time to first irAEs onset was 28 d. Most irAEs occurred at early time after treatment, and most irAEs were mild-moderate and reversible. 57 patients (42.2%) died at the study cutoff. The mortality rate of severe irAEs was 12.6% (n=17), and among them 7 patients (41.2%) died of pneumonitis. The median progression-free survival (PFS) and overall survival (OS) time of the total population was 505 d (95%CI: 352-658) and 625 d (95%CI: 491-759), respectively. Patients who presented any irAEs achieved a longer PFS than those who did not (median PFS: 533 d vs 179 d, P=0.037, HR=0.57), while patients who presented skin toxicities achieved a longer OS than patients who did not (median OS: 797 d vs 469 d, P=0.006, HR=0.70).In real-world settings, irAEs in lung cancer patients were commonly observed, with pneumonitis as the most common fatal irAEs. In addition, patients who presented any irAEs may tend to achieve a longer PFS.【中文题目：免疫相关不良事件在肺癌中发生和结局的 真实世界研究】 【中文摘要：背景与目的 免疫相关不良事件（immune-related adverse events, irAEs）常发生于免疫检查点抑制剂应用的患者，但关于肺癌中irAEs发生和结局的国内证据相对缺乏。本研究旨在评估中国肺癌患者接受免疫治疗后irAEs的发生和转归。方法 纳入2018年1月-2021年9月在复旦大学附属华东医院接受过至少1次免疫检查点抑制剂治疗的肺癌患者的临床和随访资料，通过统计描述、Kaplan-Meier等方法分析irAEs总体发生情况及各类irAEs的发生与结局。结果 共纳入135例患者，106例（78.5%）至少发生一种irAEs，首次发生的中位时间为28 d。多数irAEs发生于治疗早期，多为轻-中度、可恢复。57例（42.2%）患者死亡；严重irAEs致死率为12.6%（n=17），其中7例（41.2%）死于肺炎。整体人群的中位无进展生存期（progression-free survival, PFS）为505 d（95%CI: 352-658），中位总生存期（overall survival, OS）为625 d（95%CI: 491-759）。发生任一irAEs患者的PFS长于治疗未发生者（中位PFS分别为533 d和179 d，P=0.037；HR=0.57）；发生皮肤毒性者的OS长于未发生者（中位OS分别为797 d和469 d，P=0.006；HR=0.70）。结论 真实世界中肺癌患者irAEs普遍发生，其中肺炎为最常见的致死性irAEs，发生irAEs患者群体存在PFS上的优势。 】 【中文关键词：肺肿瘤；免疫相关不良事件；免疫治疗；生存期】." @default.
• W4376643030 created "2023-05-17" @default.
• W4376643030 creator A5012856804 @default.
• W4376643030 creator A5015625878 @default.
• W4376643030 creator A5046415067 @default.
• W4376643030 date "2023-04-20" @default.
• W4376643030 modified "2023-09-28" @default.
• W4376643030 title "[A Real-world Study on the Incidence and Outcome of Immune-related Adverse Events in Lung Cancer Patients]." @default.
• W4376643030 cites W2097995306 @default.
• W4376643030 cites W2265285917 @default.
• W4376643030 cites W2347141054 @default.
• W4376643030 cites W2473218705 @default.
• W4376643030 cites W2508205285 @default.
• W4376643030 cites W2527905628 @default.
• W4376643030 cites W2549481046 @default.
• W4376643030 cites W2614467908 @default.
• W4376643030 cites W2736166064 @default.
• W4376643030 cites W2783137027 @default.
• W4376643030 cites W2786816161 @default.
• W4376643030 cites W2805602843 @default.
• W4376643030 cites W2884450301 @default.
• W4376643030 cites W2889043644 @default.
• W4376643030 cites W2945590213 @default.
• W4376643030 cites W2999042597 @default.
• W4376643030 cites W3034596577 @default.
• W4376643030 cites W3080803693 @default.
• W4376643030 cites W3107870684 @default.
• W4376643030 cites W3128782849 @default.
• W4376643030 cites W3132509156 @default.
• W4376643030 cites W3148902978 @default.
• W4376643030 cites W3215644018 @default.
• W4376643030 cites W4210370153 @default.
• W4376643030 cites W4223614330 @default.
• W4376643030 cites W4292183344 @default.
• W4376643030 cites W4311379484 @default.
• W4376643030 cites W4318067205 @default.
• W4376643030 cites W4320495733 @default.
• W4376643030 doi "https://doi.org/10.3779/j.issn.1009-3419.2023.101.08" @default.
• W4376643030 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37183640" @default.
• W4376643030 hasPublicationYear "2023" @default.
• W4376643030 type Work @default.
• W4376643030 citedByCount "0" @default.
• W4376643030 crossrefType "journal-article" @default.
• W4376643030 hasAuthorship W4376643030A5012856804 @default.
• W4376643030 hasAuthorship W4376643030A5015625878 @default.
• W4376643030 hasAuthorship W4376643030A5046415067 @default.
• W4376643030 hasConcept C120665830 @default.
• W4376643030 hasConcept C121332964 @default.
• W4376643030 hasConcept C121608353 @default.
• W4376643030 hasConcept C126322002 @default.
• W4376643030 hasConcept C197934379 @default.
• W4376643030 hasConcept C2776256026 @default.
• W4376643030 hasConcept C2777714996 @default.
• W4376643030 hasConcept C2779524853 @default.
• W4376643030 hasConcept C2908647359 @default.
• W4376643030 hasConcept C61511704 @default.
• W4376643030 hasConcept C71924100 @default.
• W4376643030 hasConcept C99454951 @default.
• W4376643030 hasConceptScore W4376643030C120665830 @default.
• W4376643030 hasConceptScore W4376643030C121332964 @default.
• W4376643030 hasConceptScore W4376643030C121608353 @default.
• W4376643030 hasConceptScore W4376643030C126322002 @default.
• W4376643030 hasConceptScore W4376643030C197934379 @default.
• W4376643030 hasConceptScore W4376643030C2776256026 @default.
• W4376643030 hasConceptScore W4376643030C2777714996 @default.
• W4376643030 hasConceptScore W4376643030C2779524853 @default.
• W4376643030 hasConceptScore W4376643030C2908647359 @default.
• W4376643030 hasConceptScore W4376643030C61511704 @default.
• W4376643030 hasConceptScore W4376643030C71924100 @default.
• W4376643030 hasConceptScore W4376643030C99454951 @default.
• W4376643030 hasIssue "4" @default.
• W4376643030 hasLocation W43766430301 @default.
• W4376643030 hasOpenAccess W4376643030 @default.
• W4376643030 hasPrimaryLocation W43766430301 @default.
• W4376643030 hasRelatedWork W1580426574 @default.
• W4376643030 hasRelatedWork W1970383787 @default.
• W4376643030 hasRelatedWork W2043123170 @default.
• W4376643030 hasRelatedWork W2089620537 @default.
• W4376643030 hasRelatedWork W2275480158 @default.
• W4376643030 hasRelatedWork W2390152934 @default.
• W4376643030 hasRelatedWork W2409957712 @default.
• W4376643030 hasRelatedWork W3095306390 @default.
• W4376643030 hasRelatedWork W4238089809 @default.
• W4376643030 hasRelatedWork W4241346791 @default.
• W4376643030 hasVolume "26" @default.
• W4376643030 isParatext "false" @default.
• W4376643030 isRetracted "false" @default.
• W4376643030 workType "article" @default.